Immage Biotherapeutics Corp. (IMMG) Stock

About Immage Biotherapeutics Corp.

Presently, Immage Biotherapeutics Corp. lacks substantial business operations. Historically, its endeavors centered on the creation of cutting-edge immunotherapy biologics designed to combat diverse cancer types across the United States. Established in 2012, the entity was initially known as Epicure Charcoal, Inc., rebranding to Immage Biotherapeutics Corp. in June 2015. Its corporate headquarters are situated in Bethesda, Maryland, and it operates as a subsidiary of Coventry International Limited.

Immage Biotherapeutics Corp. (IMMG) stock trades at $0.00 with a market capitalization of $15174. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.07, reflecting a net loss over the last twelve months, price-to-book of 0.08, price-to-sales of 0.00.

On profitability, Immage Biotherapeutics Corp. generates a return on equity (ROE) of -200.39% (negative, reflecting a net loss), return on capital employed of -115.58%.

Official website: www.immagebio.com